NOVEMBER 2023LIFE SCIENCES REVIEW6Digital therapeutics play a crucial role in the healthcare revolution, revamping how patients access, engage with and manage their diseases. These cutting-edge treatments facilitate remote care, bolstering heightened patient engagement, strengthening treatment adherence, and, ultimately, superior health outcomes. Through a fusion of advanced technology and evidence-based interventions, digital therapeutics seamlessly bridge existing gaps in healthcare delivery, leading to comprehensive enhancements in overall health and well-being.The European market for digital therapeutics is experiencing remarkable growth, with innovative startups and established pharmaceutical companies investing in research and development. Collaboration between technology firms, healthcare providers, and regulators creates an environment that promotes widespread adoption. By cultivating a strong ecosystem that supports innovation and encourages collaboration, Europe can continue to be at the forefront of therapeutic advancements, benefiting the continent and the global healthcare community.In this edition of Life Sciences Review Europe, we showcase European therapeutics companies leading the way in innovation. With remarkable breakthroughs in medical research and cutting-edge technology, these companies spearhead the development of novel therapeutics, offering hope to patients in need. Among the featured biopharmaceutical companies are Mikrobiomik, JE PolyDesign, and Celtic Biotech, dedicated to the research, development, and production of biological medicines rooted in the human microbiome. With an unwavering focus on tackling severe diseases that lack therapeutic alternatives, these companies are paving the way for a new generation of biological medicines derived from the human microbiome. The magazine further features the insightful opinions of industry experts at the forefront of healthcare innovation. Tara Moroz, PhD, Sr. director of genetic medicine and early pipeline at Pfizer, Inc., Brian D. Fry, senior director of cell therapy CDMO at Charles River Laboratories, and Hong Ma, MD, Sr. vice president of clinical development at CARsgen Therapeutics, provide their valuable perspectives on the potential of transformative therapies in revolutionizing healthcare. Their thoughts shed light on how these groundbreaking treatments offer hope and promise for individuals battling challenging diseases. The invaluable insights shared by these esteemed leaders featured in this edition will greatly assist you in making informed decisions for your businesses.Let us know your thoughts!EDITORIALDigital Therapeutics Pioneering the Future of Healthcare in EuropeCopyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasGilbert HooverAncel CastelinoDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsNovember - 29 - 2023, Vol 04, Issue - 28 ( ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com VisualizersRonald DonovanVictor Cruz Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.comPENDING
< Page 5 | Page 7 >